CGEM (NASDAQ) - Cullinan Oncology LLC

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2300311063
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for CGEM (NASDAQ) - Cullinan Oncology LLC


Market Cap in USD 450m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2021-01-08


Fundamental -2.77
Dividend -
Performance 5y -6.03
Rel. Performance vs Sector -0.95
Analysts 4.60
Fair Price Total Ret. 7.36
Fair Price DCF todo


Growth TTM -28.52%
CAGR 5y -26.50%
CAGR / Mean Drawdown 5y -0.41
Sharpe Ratio TTM -0.67
Alpha vs SP500 TTM -49.39
Beta vs SP500 5y weekly 1.06
CAPM 7.63%
Average Daily Range 2m 5.07%
Reversal Oscillator 8.45
Volatility GJR Garch 1y 52.04%
Price / SMA 50 -12.22%
Price / SMA 200 -15.42%
Current Volume 129.8k
Average Volume 20d 175.9k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%